| 000 | 01427 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250518033508.0 | ||
| 264 | 0 | _c20200224 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a2052-1707 | ||
| 024 | 7 |
_a10.1002/prp2.473 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRosebraugh, Matthew | |
| 245 | 0 | 0 |
_aLevodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. _h[electronic resource] |
| 260 |
_bPharmacology research & perspectives _c04 2019 |
||
| 300 |
_ae00473 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarbidopa _xadverse effects |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aDrug Liberation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGels |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 700 | 1 | _aKalluri, Hari V | |
| 700 | 1 | _aLiu, Wei | |
| 700 | 1 | _aLocke, Charles | |
| 700 | 1 | _aSidhu, Dilraj | |
| 700 | 1 | _aHan, Jian-Hwa | |
| 700 | 1 | _aBenesh, Janet | |
| 773 | 0 |
_tPharmacology research & perspectives _gvol. 7 _gno. 2 _gp. e00473 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/prp2.473 _zAvailable from publisher's website |
| 999 |
_c29581043 _d29581043 |
||